Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • The New Market Backdrop: Stronger Growth, Tighter Labor, and Higher Rates

    A stronger economy and persistent inflation are creating a new playbook for investors.

    Read more

  • Vor Biopharma Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Vor Biopharma Inc. (VOR $18.04), a clinical-stage biotechnology company developing novel therapies to treat autoimmune disorders by targeting autoreactive B-cell biology.

    Read more

  • The A, B, C, and Ds of Medicare

    Medicare Open Enrollment ends December 7. Here's what you should know about coverage options, costs, and deadlines before you make your decisions.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures